REGN SignalReason for this trade
1: Market is taking pullback from trendline
2: market is near high supply area
Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
43.23 USD
3.95 B USD
13.12 B USD
105.92 M
About Regeneron Pharmaceuticals, Inc.
Sector
CEO
Leonard S. Schleifer
Headquarters
Tarrytown
Website
Founded
1988
FIGI
BBG000C734W3
Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. Its product portfolio includes the following brands: Dupixent, Evkeeza, Eylea, Inmazeb, and Kevzara. The firm accelerates the traditional drug development process through its proprietary VelociSuite technologies such as VelocImmune, which uses unique genetically humanized mice to produce optimized fully human antibodies and bispecific antibodies. The company was founded by Alferd G. Gilman, Leonard S. Schleifer, George Damis Yancopoulos, and Eric M. Shooter on January 8, 1988, and is headquartered in Tarrytown, NY.
An aggregate view of professional's ratings.
Displays a symbol's price movements over previous years to identify recurring trends.
REGN5027988
Regeneron Pharmaceuticals, Inc. 2.8% 15-SEP-2050Yield to maturity
7.11%
Maturity date
Sep 15, 2050
REGN5027987
Regeneron Pharmaceuticals, Inc. 1.75% 15-SEP-2030Yield to maturity
5.43%
Maturity date
Sep 15, 2030
Explore more bonds
Curated watchlists where REGN is featured.
Frequently Asked Questions
The current price of REGN is 731.30 USD — it has decreased by −1.31% in the past 24 hours. Watch Regeneron Pharmaceuticals, Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Regeneron Pharmaceuticals, Inc. stocks are traded under the ticker REGN.
REGN stock has fallen by −4.86% compared to the previous week, the month change is a −10.32% fall, over the last year Regeneron Pharmaceuticals, Inc. has showed a −16.31% decrease.
We've gathered analysts' opinions on Regeneron Pharmaceuticals, Inc. future price: according to them, REGN price has a max estimate of 1,230.00 USD and a min estimate of 565.00 USD. Watch REGN chart and read a more detailed Regeneron Pharmaceuticals, Inc. stock forecast: see what analysts think of Regeneron Pharmaceuticals, Inc. and suggest that you do with its stocks.
REGN reached its all-time high on Aug 27, 2024 with the price of 1,211.20 USD, and its all-time low was 3.00 USD and was reached on Dec 29, 1994. View more price dynamics on REGN chart.
See other stocks reaching their highest and lowest prices.
See other stocks reaching their highest and lowest prices.
REGN stock is 1.69% volatile and has beta coefficient of 0.82. Track Regeneron Pharmaceuticals, Inc. stock price on the chart and check out the list of the most volatile stocks — is Regeneron Pharmaceuticals, Inc. there?
Today Regeneron Pharmaceuticals, Inc. has the market capitalization of 81.42 B, it has increased by 5.13% over the last week.
Yes, you can track Regeneron Pharmaceuticals, Inc. financials in yearly and quarterly reports right on TradingView.
Regeneron Pharmaceuticals, Inc. is going to release the next earnings report on Jan 31, 2025. Keep track of upcoming events with our Earnings Calendar.
REGN earnings for the last quarter are 12.46 USD per share, whereas the estimation was 11.69 USD resulting in a 6.54% surprise. The estimated earnings for the next quarter are 11.27 USD per share. See more details about Regeneron Pharmaceuticals, Inc. earnings.
Regeneron Pharmaceuticals, Inc. revenue for the last quarter amounts to 3.72 B USD, despite the estimated figure of 3.67 B USD. In the next quarter, revenue is expected to reach 3.76 B USD.
REGN net income for the last quarter is 1.34 B USD, while the quarter before that showed 1.43 B USD of net income which accounts for −6.40% change. Track more Regeneron Pharmaceuticals, Inc. financial stats to get the full picture.
No, REGN doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Dec 14, 2024, the company has 13.45 K employees. See our rating of the largest employees — is Regeneron Pharmaceuticals, Inc. on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Regeneron Pharmaceuticals, Inc. EBITDA is 4.61 B USD, and current EBITDA margin is 36.36%. See more stats in Regeneron Pharmaceuticals, Inc. financial statements.
Like other stocks, REGN shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Regeneron Pharmaceuticals, Inc. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Regeneron Pharmaceuticals, Inc. technincal analysis shows the strong sell today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Regeneron Pharmaceuticals, Inc. stock shows the sell signal. See more of Regeneron Pharmaceuticals, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.